Watching Biohaven; Shares Trade Higher As Co Releases Presentation, Including Pharmacodynamic Updates For BHV-1300, The Co's Bispecific IgG Degrader, Showing Greater Than 90% Reductions In IgG After Repeat Dosing And Is Incorporated Herein By Reference
Portfolio Pulse from Benzinga Newsdesk
Biohaven's shares are trading higher following the company's presentation, which included pharmacodynamic updates for BHV-1300. The bispecific IgG degrader showed over 90% reductions in IgG after repeat dosing, according to an SEC filing.
September 27, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biohaven's stock is trading higher after the company revealed positive updates for its bispecific IgG degrader, BHV-1300, which showed over 90% reductions in IgG after repeat dosing.
The positive updates on Biohaven's BHV-1300, which showed significant reductions in IgG, are likely to boost investor confidence in the company's product pipeline and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100